CLEARSIDE BIOMEDICAL

Clearside Biomedical Expands XIPERE™ License Agreement with Arctic Vision to Include Australia, New Zealand, India and ASEAN Countries

09 سبتمبر 2021 07:05:00 بحسب Nasdaq GlobeNewswire

Clearside Biomedical to Present at the Ophthalmology Futures European 2021 Virtual Retina Forum

23 أغسطس 2021 16:05:00 بحسب Nasdaq GlobeNewswire

Clearside Biomedical Announces Second Quarter 2021 Financial Results and Provides Corporate Update

10 أغسطس 2021 16:05:00 بحسب Nasdaq GlobeNewswire

Clearside Biomedical to Participate in Two Upcoming Investor Conferences in August 2021

04 أغسطس 2021 07:05:00 بحسب Nasdaq GlobeNewswire

Clearside Biomedical to Report Second Quarter 2021 Financial Results and Provide Corporate Update on Tuesday, August 10, 2021

27 يوليو 2021 16:05:02 بحسب Nasdaq GlobeNewswire

Clearside Biomedical Announces Positive Safety Results from Cohort 1 of OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD

15 يونيو 2021 07:05:00 بحسب Nasdaq GlobeNewswire

Clearside Biomedical to Participate in Two Upcoming Investor Conferences in June 2021

09 يونيو 2021 07:05:00 بحسب Nasdaq GlobeNewswire

Clearside Biomedical Announces First Quarter 2021 Financial Results and Provides Corporate Update

17 مايو 2021 16:05:01 بحسب Nasdaq GlobeNewswire

Clearside Biomedical Announces Multiple Poster Presentations at the Association for Research in Vision and Ophthalmology 2021 Virtual Meeting

10 مايو 2021 07:05:00 بحسب Nasdaq GlobeNewswire

Clearside Biomedical to Report First Quarter 2021 Financial Results and Provide Corporate Update on Monday, May 17, 2021

04 مايو 2021 07:05:00 بحسب Nasdaq GlobeNewswire

Clearside Biomedical Announces Resubmission of New Drug Application for XIPERE™ for Treatment of Macular Edema Associated with Uveitis

03 مايو 2021 07:05:00 بحسب Nasdaq GlobeNewswire

Clearside Biomedical to Present at the Needham Virtual Healthcare Conference and Wet AMD & DME Drug Development Summit

05 أبريل 2021 07:05:00 بحسب Nasdaq GlobeNewswire

Clearside Biomedical Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

10 مارس 2021 16:05:01 بحسب Nasdaq GlobeNewswire

Clearside Biomedical Announces Completion of Patient Dosing in First Cohort of Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD

02 مارس 2021 07:05:00 بحسب Nasdaq GlobeNewswire

Clearside Biomedical to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update on Wednesday, March 10, 2021

24 فبراير 2021 07:05:00 بحسب Nasdaq GlobeNewswire

Clearside Biomedical to Participate in Two Upcoming Investor Conferences in March 2021

23 فبراير 2021 07:05:00 بحسب Nasdaq GlobeNewswire

Clearside Biomedical Announces CLS-AX (axitinib injectable suspension) Presentation Delivered at Angiogenesis, Exudation, and Degeneration 2021 Program

16 فبراير 2021 07:05:00 بحسب Nasdaq GlobeNewswire

Clearside Biomedical Featured in Multiple Data Presentations at the 44th Virtual Annual Macula Society Meeting

08 فبراير 2021 07:05:00 بحسب Nasdaq GlobeNewswire

Clearside Biomedical Announces First Patients Enrolled in Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD

12 يناير 2021 07:05:00 بحسب Nasdaq GlobeNewswire

Clearside Biomedical Announces Pricing of $12 Million Registered Direct Offering

06 يناير 2021 07:05:00 بحسب Nasdaq GlobeNewswire